

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 4, 2010**

iBio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

000-53125

(Commission File Number)

26-2797813

(IRS Employer Identification No.)

9 Innovation Way, Suite 100

Newark, Delaware 19711

(Address of principal executive offices, including zip Code)

(302) 355-0650

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On June 7, 2010, iBio, Inc. (the “Company” or “iBio”) will present at the Noble Financial Sixth Annual Equity Conference. During this presentation, the Company will discuss its business strategy, technology and financial outlook. A copy of the materials to be used in conjunction with the presentation is furnished as Exhibit 99.1 hereto.

On June 4, 2010, the Company issued a press release announcing its participation at this conference. A copy of the press release is furnished as Exhibit 99.2 hereto.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly stated by specific reference in such filing.

This report and the attached exhibits may contain forward-looking statements, including statements as to anticipated or expected results, beliefs, opinions and future financial performance, within the meaning of Section 21E of the Securities and Exchange Act of 1934. Such forward-looking statements involve risks and uncertainties. These forward-looking statements are not historical facts but rather are plans and predictions based on current expectations, estimates and projections about the Company’s industry, beliefs and assumptions. The Company uses words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond the Company’s control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These risks and uncertainties include those described in the Company’s reports pursuant to the Securities and Exchange Act of 1934, as amended, in the section entitled “Risk Factors.”

The Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation of iBio, inc. dated June 2010
99.2	Press Release of iBio, Inc., issued June 4, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

IBIO, INC.

Date: June 4, 2010

By: /s/ Frederick Larcombe

Frederick Larcombe
Chief Financial Officer



Game-Changing Technology for the Vaccine
and Therapeutic Biologics Business

Noble Financial Sixth Annual Equity Conference

ONTRACK 2010

© iBio, Inc. 2010

Proprietary and Confidential



SAFE HARBOR STATEMENT

- This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. These risks and uncertainties are discussed in our registration statement on file with the Securities and Exchange Commission. Unless required by law, the company undertakes no obligation to update publicly any forward-looking statements.

iBio

iBioLaunch Platform: Best Technology for New Influenza Vaccines



Photo from Medicinenet.com

Traditional: Egg Technology

- Slow
- Expensive
- Some Flu Viruses Kill Eggs



Photo from Novartis

Newer: Animal Cell Technology

- Expensive Facilities
- High Cost of Goods
- Contamination Concerns



Best: iBioLaunch Technology

- Rapid Production Cycles
- Low Capital and COGs
- Surge Capacity
- No Animal/Human Pathogens





How Will iBio Create Shareholder Value?

- **High-Reward / Low-Risk Business Strategy**
 - Broadly-sourced license revenue from defined product categories and geographic regions – corporations & governments
 - Value-enhancing early-stage development and co-development of products
- **Based on Disruptive iBioLaunch™ Platform Technology**
 - Significant cost, time, safety and freedom-to-operate advantages
- **With Substantial Non-dilutive Financing**
 - Over \$70 million invested to date by government agencies and NGOs
 - \$15 million pilot plant funded by U.S. government
 - New third-party commitments of \$9.8 million for malaria, \$4.4 million for H1N1 flu, and \$5.3 million for anthrax-plague
 - External funding committed for two Phase 1 clinical trials – 2010





A Substantial Business Opportunity: Address International Needs for a Flexible and Efficient Vaccine and Protein Manufacturing Platform

“For generations, the United States has neglected to nurture the technologies and systems needed to respond to emergencies related to disease. Nowhere has this been more evident than in the response to H1N1.”

“In six to nine months last year, the United States was able to identify this new H1N1 virus, make vaccine and begin distributing it, though in inadequate amounts. There is no other disease to which our public health infrastructure could respond anywhere near as quickly. For most new diseases, the response time would be more like six to nine years.”

Bob Graham & Jim Talent
Washington Post, January 4, 2010

“Some analysts state that the availability of more expensive, state-of-the-art technological services and new drugs fuel health care spending not only because the development costs of these products must be recouped by industry but also because they generate consumer demand for more intense, costly services even if they are not necessarily cost-effective.”

Kaiser Family Foundation,
March 2010, citing
Congressional Budget Office



iBio's Proprietary Technology Enables Flexible and Efficient Bio-Product Manufacturing

- **iBio Opportunities: Vaccines and Bio-defense**
 - Corporations seek entry into lucrative vaccine markets
 - Nations seek regional autonomy for response to outbreaks and/or bio-defense
- **iBio Opportunities: Therapeutic Proteins**
 - Corporations seek to enter orphan medical markets
 - Corporations seek to launch “bio-similar” or “bio-better” products

iBio



Problem: Nations Are Poorly Prepared for Pandemics

“Pandemics are global but political calculation to confront them is decidedly local,” Yanzhong Huang, YaleGlobal – September 2009

Federal officials [predicted](#) that 160 million doses of H1N1 vaccine would be available by October. In reality, there were [fewer than 30 million](#) by that time. Former U.S. Senators Bob Graham (D-Florida) and Jim Talent (R-Missouri) wrote a scathing January 4 editorial blaming the shortage on U.S. failure to “nurture the technologies and systems needed.” – CSIS, January 2010

“Recent clinical, epidemiological and laboratory evidence suggests that the impact of a pandemic caused by the current H5N1 strain would be similar to that of the 1918-19 pandemic,” Michael T. Osterholm, Ph.D., MPH, Director, Center for Infectious Disease Research and Policy, 2008

Problem: Bio-Terrorist Attacks Are Inevitable



- Washington Post – **December 29, 2004** – “Only a thin wall of terrorist ignorance and inexperience now protects us.” -- Richard Danzig, former Navy Secretary and Pentagon bioterrorism consultant



- CNN – **January 26, 2010** – “A commission set up to assess national security measures on Tuesday gave the U.S. government a failing grade in improving response time to a biological attack.”

iBio



The iBio Solution

Deployment of the iBioLaunch™ Platform to Produce Vaccines for Pandemic Outbreaks and Combat Bioterrorism

- **Dramatic Improvement in Speed of Response**
 - Days and weeks versus months
- **Location Flexibility and Practical Surge Capacity**
 - Modular design and ease of tech transfer enable regional autonomy or decentralized manufacturing
 - Scalability not constrained by biological limitations of fermentation and cell culture methods, nor by equipment fabrication times
- **Substantial Reduction in Capital Requirements for Scale**
 - Less than **\$100 million** capital investment targets capacity of 1.2 billion doses per year (U.S. government-sponsored facility)
Press reports state that a cell-based facility under development will require **\$1 billion** for a capacity of only 150 million doses per year

iBio



Third Party Investments in iBioLaunch Platform Vaccine Applications

- The Bill & Melinda Gates Foundation and the Sabin Vaccine Institute - \$ 33.3 million for iBioLaunch platform applications
 - Avian Influenza Vaccine - \$ 11.4 million
 - Malaria Vaccine - \$ 13.3 million
 - Sleeping Sickness Vaccine - \$ 8.2 million
- Hookworm Vaccine - \$ 0.4 million
- U.S. Government - \$ 37.4 million for iBioLaunch platform applications
 - Accelerated Manufacturing Program - \$ 14.8 million
 - H1N1 Influenza Vaccine - \$ 4.4 million
 - Plague-Anthrax Combination Vaccine - \$ 18.2 million

iBio



iBio Opportunities: Corporations Entering Vaccine Markets & Nations Recognizing Pandemic Disease and Bioterrorism as National Security Threats

1. iBioLaunch technology superior for recombinant vaccines in comparison to bioreactor based systems
 - No animal components or human pathogens
 - Lower cost of goods
 - Rapid batch production cycles
 - Excellent surge capacity
 - Not dependent on access to culturable pathogens
2. iBioLaunch technology can be rapidly implemented at substantially lower capital costs than conventional methods for vaccine active ingredient manufacturing 10 to 15 percent in comparison to animal cell / virus culture methods





The Market for New and Expanded Vaccine and Bio-defense Applications

-
- Global vaccine market projected at \$32 billion in 2012
- Influenza vaccine market projected \geq \$4 billion in 2010

Bio-defense Vaccines

- U.S. spending for 2010 approximately \$5 billion

Tropical Diseases

Gates Global Access Agreement

- Malaria is endemic in 117 countries (2.5 billion people)
- Hookworm infects approximately 700 million people worldwide
- iBio is the preferred tech transfer supplier and has right of first refusal to manufacture

iBio



iBio Opportunities: Corporations Developing Protein Therapeutics

- **Orphan Medical Products**
 - iBioLaunch technology flexibility makes feasible addressing small population, high-value proteins
 - **Bio-similar and Bio-better Products**
 - iBioLaunch technology is applicable to all currently marketed biotech therapeutic proteins
 - iBioLaunch technology can be used to rapidly evaluate and develop proprietary and improved derivatives of existing products
- Capital and cost of goods advantage over standard methods, making iBio a partner of choice for new biologics being developed by others

iBio



The iBio Solution

Advantages of iBioLaunch™ Technology For Therapeutic Protein Manufacturing

- **Best Economy of Production**
 - Reduced cost of materials, More efficient space utilization, Lower process costs, and Reduced amortization and depreciation expenses
- **Facility Expansion Efficiency**
 - Time frame to bring new facilities online dramatically shorter than conventional methods – 12 to 18 months versus 4 to 7 years
- **Broad Product Applicability**
 - Proven effective for production of monoclonal antibodies and other classes of therapeutic proteins, both proprietary and generic
- **Freedom to Operate**
 - Bioreactor & cell line patents do not apply
- **Safety**
 - Eliminates risk of live virus culture and animal-based components

iBio



Achievements of iBioLaunch Technology in Therapeutic Protein Applications:

- Efficient production of monoclonal antibodies, including proprietary product candidates for influenza and anthrax
- Proven applicable to interferons, growth factors, therapeutic enzymes, insulin, lectins, protease inhibitors, nucleases, etc.
- Functional and structural properties of iBioLaunch-produced proteins are the same as the native forms
 - Disulfide linkages
 - Glycan occupancy
 - Tissue distribution in animal studies
 - *In vivo* activity in animal studies
 - Immunogenicity (and absence thereof)

iBio



Market(s) for iBio Relevant Protein Therapeutics

- **Orphan Drug Opportunities**

- Entry enhanced by 50% orphan drug development cost U.S. tax credit
 - Novartis alone sells over **\$8 billion** in orphan drugs
 - 2,116 orphan drug designations approved by the FDA since 1983
 - Pfizer – Protalix deal validates big pharma interest
- Global market projected at **\$81 billion** next year

- **Bio-similars and Bio-betters**

- Biologics market is growing at double the pace of the pharmaceutical industry
 - This rapid growth is fueling fears regarding affordability
 - A number of biological drugs are losing patent protection
 - Companies developing bio-generics are in two main groups
 - Divisions of established generics manufacturers
 - Research-based biotech companies
- Current market estimated by Deutsche Bank at **\$26 billion**

iBio



Intellectual Property

- .Product Filings (U.S. and International)
 - Influenza vaccines
 - HPV vaccines
 - Influenza monoclonal antibodies
 - Anthrax vaccines
 - Plague vaccine
 - Trypanosomiasis and Malaria vaccines
- .Technology Filings (U.S. and International)
 - Virus-induced gene silencing in plants
 - Activation of transgenes in plants by viral vectors
 - Production of proteins in plants with launch vector
 - Transient expression of proteins in plants
 - Protein expression in seedlings and clonal root cultures
 - Thermostable carrier molecule

iBio



Fraunhofer USA CMB – iBio Relationship

- Fraunhofer USA CMB is a not-for-profit R&D organization
 - Develops plant-based technologies to develop and manufacture vaccines and therapeutic biologics
 - Specialists in vaccine development, plant molecular biology, immunology, and protein engineering
- Fraunhofer USA CMB receives grants and contracts from U.S. DoD, Bill & Melinda Gates Foundation and iBio, Inc.
- iBio owns the technology developed with all sources of funding
 - Worldwide exclusive rights in human healthcare
 - Cooperation with Gates on “Global Access” in exchange for rights of first refusal on tech transfer contracts and contract manufacturing



Synergy of iBio-CMB Collaboration Enhances Rate of Technical Innovation

- Non-dilutive and highly accretive collaboration with Fraunhofer USA CMB
- Leveraged funding for technology / product development >\$70 million through 2010
- Dec. 2009 - \$9.85 million from Bill & Melinda Gates Foundation for malaria; Ongoing funding for avian influenza vaccine clinicals
- Mar. 2010 - \$4.4 million from DARPA for H1N1 influenza vaccine
- Apr. 2010 - \$5.3 million from DTRA for combination anthrax-plague vaccine




iBio



iBioLaunch™

Accelerated High Capacity
Production of
Pharmaceutical Proteins



iBio



Management Team and Directors

- **Management**

- Robert B. Kay - CEO & Executive Chairman
- Robert Erwin - President
- Frederick Larcombe, CPA – Interim CFO
- Vidadi Yusibov, Ph.D. - Chief Scientific Officer

- **Board of Directors**

- Robert B. Kay – Executive Chairman
 - Dr. Pamela Bassett – Cantor Fitzgerald
 - Glenn Chang – First American International Bank
 - General James T. Hill (ret.) – The J.T. Hill Group
 - John D. McKey Jr. – McCarthy, Summers, Bobko, Wood, Sawyer & Perry
 - General (ret.) Philip K. Russell, M.D. – Sabin Institute
- 





iBio Valuation Metrics

- Industry Data

- Median Upfront Payments in Post-Phase 1 Clinical Development: \$20 Million (27 deals -

- ReCap)

- Product Royalties: Preclinical 0 to 5%; Clinical 5 to 10%, Launched Products 8 to 20%

- Platform Royalties: Up to 11.7%

- Addressable Markets: Total Approximately \$100 Billion

- Influenza: \$4 billion

- Other vaccines: \$30 billion

- Biogenerics: Top 8 biologics worldwide sales of \$26 billion

- Orphan Biologics: 50% of orphan drug total of \$81 billion: \$40 billion

- Imputed iBio Value

- For each 1% Market Penetration, with just a 5% Average Royalty, iBio Annual Revenues

- Would Equal \$50 million (Almost All of Which Would Fall to Bottom Line)

- Current PE ratio of exchange-traded biotech basket fund, BBH, is 14X

- At PE of 14X, market cap would equal \$700 Million per 1% Market Penetration (Without including possible upfront fees)





Recap: iBio's Value Proposition

- Diversified licensing approach to commercialize proprietary platform
 - Less capital required vs. single-product biotech
 - Non-dilutive financing enhances value
 - Superior technology with third party validation in hand
 - Large and growing markets
 - Early and low-risk revenue
- Stock is currently undervalued in comparison to peers

iBio



Financial Metrics

- Cash and Equivalents: \$1.5 million (as of 3/31/10)
- No Debt
- Stock Price: (OTCBB: IBPM) \$1.02 on 5/28/10
- Market-Cap: \$28.8 Million
- Shares Outstanding: 28.3 million
Float: 14.2 million

iBio



9 Innovation Way, Suite 100
Newark, DE 19711
www.ibioinc.com

Contact:

Robert Erwin
President
iBio, Inc.
302-355-2335

© iBio, Inc. 2010
erwin@bioinc.com

Investor Contact:

Jeffrey Benison
Managing Director
Little Gem Life Science Partners
212-334-8709

jeffrey@littlegem.us

Media Contact:

Melody A. Carey
Co-President
Rx Communications Group
917-322-2571

Proprietary and Confidential
mcarey@rxll.com



Contacts:

Robert Erwin
President
iBio, Inc.
302-355-2335
rerwin@ibioinc.com

Eric Goldman (Media)
Vice President
Rx Communications, Inc.
917-322-2563
egoldman@rxir.com

FOR IMMEDIATE RELEASE

**iBio to Present at Noble Financial Sixth Annual Equity
Conference – ONTRACK 2010**

NEWARK, DE – June 4, 2010 – iBio, Inc. (OTCBB: IBPM) today announced that Robert Erwin, President, and Dr. Vidadi Yusibov, Chief Scientific Officer, will make a presentation regarding the business strategy, technology, and financial outlook of the Company at the Noble Financial Sixth Annual Equity Conference at 8:30 am EDT on June 7, 2010, at the Hard Rock Hotel in Hollywood, Florida.

The Company will discuss the significance of the opening of the new cGMP pilot manufacturing facility in Delaware by iBio's R&D collaborator, the Fraunhofer USA Center for Molecular Biotechnology (FhCMB). This first-in-kind facility operates robotically to manufacture vaccines and therapeutic proteins using the iBioLaunch platform technology and is currently producing vaccine active ingredients for upcoming Phase 1 clinical trials. Bringing this facility online is a significant step forward in the deployment of iBio's technology for both commercial and national security applications.

The Company will also provide updates on recent developments of importance to the value of the Company's core technology assets and business prospects and discuss its program for licensing its proprietary iBioLaunch platform. Important developments include the recent issuance of three new U.S. patents covering various aspects of the iBioLaunch platform, completion of a pre-IND meeting with the FDA by FhCMB, and preparation for Phase 1 clinical trials of both avian influenza and H1N1 influenza vaccines which are expected to be completed by early 2011.

The presentation will be webcast - audio / video / PowerPoint - live, and available for viewing through the Noble Financial websites www.ontrack10.com, or www.nobleresearch.com. iBio recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SiverLight viewer (a free download from presentation link) to participate. In addition, the webcast, transcript and written materials will be archived on the Company's website for 90 days following the event.

About iBio, Inc.

iBio, Inc. is a biopharmaceutical company commercializing its proprietary technology, the iBioLaunch™ platform, for the production of biologics including vaccines and therapeutic proteins. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited to infectious disease applications where speed, scalability, and surge capacity are important. iBio's strategy is to utilize its technology for development and manufacture of its own product candidates and work with both corporate and government clients to reduce their costs during product development and meet their needs for low cost, high quality biologics manufacturing systems. iBio owns technology developed at the Fraunhofer USA Center for Molecular Biotechnology, and continues to sponsor development and refinement of the technology for broad applications in human healthcare. Further information is available at www.ibioinc.com.

About Noble Financial

Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service investment banking boutique focused on small-cap, emerging growth companies. The company has offices in New York, Boston, New Jersey, St Louis and Boca Raton.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

Statements included in this release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

###
